These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 17332049)

  • 1. The patient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical).
    Costelloe L; O'Rourke K; Kearney H; McGuigan C; Gribbin L; Duggan M; Daly L; Tubridy N; Hutchinson M
    J Neurol Neurosurg Psychiatry; 2007 Aug; 78(8):841-4. PubMed ID: 17332049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responsiveness of the Multiple Sclerosis Impairment Scale in comparison with the Expanded Disability Status Scale.
    Ravnborg M; Blinkenberg M; Sellebjerg F; Ballegaard M; Larsen SH; Sørensen PS
    Mult Scler; 2005 Feb; 11(1):81-4. PubMed ID: 15732271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures of impairment and disability.
    Hoogervorst EL; Zwemmer JN; Jelles B; Polman CH; Uitdehaag BM
    Mult Scler; 2004 Oct; 10(5):569-74. PubMed ID: 15471375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The multiple sclerosis impact scale (MSIS-29) is a reliable and sensitive measure.
    McGuigan C; Hutchinson M
    J Neurol Neurosurg Psychiatry; 2004 Feb; 75(2):266-9. PubMed ID: 14742602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tried and tested: the psychometric properties of the multiple sclerosis impact scale (MSIS-29) in a population-based study.
    Gray O; McDonnell G; Hawkins S
    Mult Scler; 2009 Jan; 15(1):75-80. PubMed ID: 18829636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The longitudinal relationship between the patient-reported Multiple Sclerosis Impact Scale and the clinician-assessed Multiple Sclerosis Functional Composite.
    Costelloe L; O'Rourke K; McGuigan C; Walsh C; Tubridy N; Hutchinson M
    Mult Scler; 2008 Mar; 14(2):255-8. PubMed ID: 17942522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The MS Impairment Scale: a pragmatic approach to the assessment of impairment in patients with multiple sclerosis.
    Ravnborg M; Grønbech-Jensen M; Jønsson A
    Mult Scler; 1997 Feb; 3(1):31-42. PubMed ID: 9160344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Responsiveness of patient reported outcome measures in multiple sclerosis relapses: the REMS study.
    Giordano A; Pucci E; Naldi P; Mendozzi L; Milanese C; Tronci F; Leone M; Mascoli N; La Mantia L; Giuliani G; Solari A
    J Neurol Neurosurg Psychiatry; 2009 Sep; 80(9):1023-8. PubMed ID: 19443471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantifying the impact of upper limb tremor on the quality of life of people with multiple sclerosis: a comparison between the QUEST and MSIS-29 scales.
    Tang CC; Soh SE; Boonstra F; Noffs G; Kolbe SC; Butzkueven H; Evans A; Van der Walt A
    Mult Scler Relat Disord; 2022 Feb; 58():103495. PubMed ID: 35085981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Validation of selected aspects of psychometry of the Polish version of the Multiple Sclerosis Impact Scale 29 (MSIS-29)].
    Jamroz-Wiśniewska A; Papuć E; Bartosik-Psujek H; Belniak E; Mitosek-Szewczyk K; Stelmasiak Z
    Neurol Neurochir Pol; 2007; 41(3):215-22. PubMed ID: 17629814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The reliability and validity of the Turkish version of the multiple sclerosis impact scale-29.
    Özden F; Özkeskin M; Yüceyar N
    Turk J Med Sci; 2022 Aug; 52(4):1216-1222. PubMed ID: 36326386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Premorbid Sociodemographic Status and Multiple Sclerosis Outcomes in a Universal Health Care Context.
    He A; Manouchehrinia A; Glaser A; Ciccarelli O; Butzkueven H; Hillert J; McKay KA
    JAMA Netw Open; 2023 Sep; 6(9):e2334675. PubMed ID: 37751208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple sclerosis impairment scale and brain MRI in secondary progressive multiple sclerosis.
    Theodorsdottir A; Larsen PV; Nielsen HH; Illes Z; Ravnborg MH
    Acta Neurol Scand; 2022 Mar; 145(3):332-347. PubMed ID: 34799851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure.
    Hobart J; Lamping D; Fitzpatrick R; Riazi A; Thompson A
    Brain; 2001 May; 124(Pt 5):962-73. PubMed ID: 11335698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the fatigue scale for motor and cognitive functions in a danish multiple sclerosis cohort.
    Oervik MS; Sejbaek T; Penner IK; Roar M; Blaabjerg M
    Mult Scler Relat Disord; 2017 Oct; 17():130-134. PubMed ID: 29055443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis.
    Ozakbas S; Cagiran I; Ormeci B; Idiman E
    J Neurol Sci; 2004 Mar; 218(1-2):3-7. PubMed ID: 14759626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How similar are commonly combined criteria for EDSS progression in multiple sclerosis?
    Kragt JJ; Nielsen IM; van der Linden FA; Uitdehaag BM; Polman CH
    Mult Scler; 2006 Dec; 12(6):782-6. PubMed ID: 17263007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the Multiple Sclerosis Impact Scale-29 (MSIS-29) have the range to capture the experience of fully ambulatory multiple sclerosis patients? Learnings from the ASCLEPIOS studies.
    Regnault A; Loubert A; Brennan R; Meunier J; Naujoks C; Cano S; Adlard N
    Mult Scler J Exp Transl Clin; 2023; 9(3):20552173231201422. PubMed ID: 37780483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detecting clinically-relevant changes in progressive multiple sclerosis.
    Bosma LV; Sonder JM; Kragt JJ; Polman CH; Uitdehaag BM
    Mult Scler; 2015 Feb; 21(2):171-9. PubMed ID: 25013153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.